Simpson Thacher recently represented the underwriters, led by J.P. Morgan, TD Cowen, Jefferies and Stifel, in connection with the registered follow-on offering of 5,750,000 shares of Class A common stock by Nuvalent, Inc. (“Nuvalent”). The offering raised approximately $540.5 million in gross proceeds.~~Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.~~The Simpson Thacher team included John O'Connell, John C. Ericson, Art Robinson, Julie De Keukeleire and Anna Jarman (Capital Markets); Vanessa Burrows and Jacob Madden (Healthcare); Paige Brinton (IP); Drew Purcell and Michael Mann (Tax); Pasco Struhs (ECEB); and Andrew Pagliughi (FINRA and Blue Sky).